PBLA (Panbela Therapeutics) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Panbela Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Panbela Therapeutics  (OTCPK:PBLA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Panbela Therapeutics Cyclically Adjusted PB Ratio Related Terms


Panbela Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Panbela Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panbela Therapeutics Cyclically Adjusted PB Ratio Chart

Panbela Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Panbela Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

PBLA vs VINC, OMGAQ, ENDV: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Panbela Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panbela Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panbela Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Panbela Therapeutics's Cyclically Adjusted PB Ratio falls into.



Panbela Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Panbela Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Panbela Therapeutics's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-3.742/315.3010*315.3010
=-3.742

Current CPI (Sep. 2024) = 315.3010.

Panbela Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201412 -68,025.390 234.812 -91,343.175
201503 -81,156.410 236.119 -108,372.038
201506 -94,691.718 238.638 -125,111.648
201509 -15,969.059 237.945 -21,160.605
201512 -21,524.911 236.525 -28,693.905
201603 -28,105.292 238.132 -37,213.086
201606 -19,866.188 241.018 -25,989.050
201609 -26,163.790 241.428 -34,169.480
201612 -34,597.355 241.432 -45,182.828
201703 2,226.453 243.801 2,879.409
201706 -6,244.442 244.955 -8,037.716
201709 -13,724.774 246.819 -17,532.828
201712 -23,046.335 246.524 -29,475.964
201803 -13,600.882 249.554 -17,184.143
201806 521.678 251.989 652.749
201809 -2,570.449 252.439 -3,210.539
201812 1,266.769 251.233 1,589.813
201903 -2,783.245 254.202 -3,452.215
201906 -490.729 256.143 -604.066
201909 8,655.580 256.759 10,629.084
201912 5,012.586 256.974 6,150.324
202003 2,620.298 258.115 3,200.831
202006 5,432.706 257.797 6,644.521
202009 23,750.218 260.280 28,770.814
202012 20,979.206 260.474 25,395.105
202103 18,041.264 264.877 21,475.736
202106 14,030.913 271.696 16,282.761
202109 24,051.537 274.310 27,645.633
202112 18,230.666 278.802 20,617.310
202203 11,743.819 287.504 12,879.257
202206 -5,589.282 296.311 -5,947.488
202209 -9,557.305 296.808 -10,152.785
202212 -4,600.989 296.797 -4,887.841
202303 94.535 301.836 98.752
202306 36.768 305.109 37.996
202309 -16.574 307.789 -16.979
202312 -9.812 306.746 -10.086
202403 -0.656 312.332 -0.662
202406 -2.177 314.175 -2.185
202409 -3.742 315.301 -3.742

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Panbela Therapeutics Business Description

Address 712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.